Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 40% of FD Patients Complain of Abdominal Distention
January 23, 2006
- 3 New Procedures to Be Covered by Insurance in April
January 23, 2006
- R&D NEWS IN BRIEF
January 23, 2006
- NEW PRODUCTS
January 23, 2006
- TOPICS 3 articles
January 23, 2006
- JPMA Approves FY2006 Action Plan
January 23, 2006
- Review Process Will Be Speeded Up in 2nd Half of FY2006: PMDA Director Miyajima
January 23, 2006
- SEMINAR
January 23, 2006
- Mr Matsutani of HPB Supports Revised Prescription Form
January 23, 2006
- Eligibility Criteria for DPC Approved: Chuikyo
January 23, 2006
- Korosho Proposes Addition, Not Replacement of Prescription Form
January 23, 2006
- REGULATORY NEWS IN BRIEF
January 16, 2006
- Nippon Shinyaku Licenses CML Treatment NS-187 to INNOVIVE of the US
January 16, 2006
- BUSINESS NEWS IN BRIEF
January 16, 2006
- SELF-MEDICATION NEWS IN BRIEF
January 16, 2006
- More Drugs to Come from Bio-ventures than Drug Firms: Prof. Morishita of AnGes MG
January 16, 2006
- Pharma Industry Invested \906.7 Bil. in R&D in FY2004
January 16, 2006
- JMA to Support IIT through Training, Information Supply
January 16, 2006
- Mr Takeda of FPMAJ Stresses Importance of Market Price Principle
January 16, 2006
- R&D NEWS IN BRIEF
January 16, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…